CLLS 6-K
Cellectis S.A. (CLLS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: September 1, 2026
Commission File Number: 001-36891
Cellectis S.A.
(Exact Name of registrant as specified in its charter)
8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
EXHIBIT INDEX
| Exhibit | Title | |
|---|---|---|
| 99.1 | Press release, dated September 1, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cellectis S.A. | |
|---|---|
| (Registrant) | |
| Date: September 1, 2026 | /s/ André Choulika |
| André Choulika | |
| Chief Executive Officer |
EdgarFiling
EXHIBIT 99.1
Cellectis Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences:
Wells Fargo 21st Annual Healthcare Conference – Boston, MA
September 10, 2026
Baird 2026 Global Healthcare Conference – New York
September 15, 2026
Company presentation at 12:50 - 1:20 p.m. ET
Fall Focus: Barclays Biotech 1x1 Day – New York
October 6, 2026
Stifel 2026 Healthcare Conference – New York
November 10-12, 2026
Jefferies Global Healthcare Conference – London
November 16-19, 2026
Cellectis' management team will be available for meetings with investors throughout these conferences. To arrange a meeting, please contact the respective conference representatives or Cellectis Investor Relations at [email protected]
Any available webcast will be posted to the Company's website at https://www.cellectis.com/en/investors/events-and-webcasts/.
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, [email protected]
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, [email protected]
Attachment
- PRESS RELEASE_Q4 2026 conference attendance_EN (https://ml.globenewswire.com/Resource/Download/2c87b37f-eaad-4e5a-9d0e-2c878845c025)